A Phase 3 Randomized, Open-Label Study Comparing Pexa Vec (Vaccinia GM CSF / Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) Without Prior Systemic Therapy

Trial Profile

A Phase 3 Randomized, Open-Label Study Comparing Pexa Vec (Vaccinia GM CSF / Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) Without Prior Systemic Therapy

Recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Sep 2017

At a glance

  • Drugs Pexastimogene devacirepvec (Primary) ; Sorafenib
  • Indications Liver cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms PHOCUS
  • Sponsors SillaJen Biotherapeutics
  • Most Recent Events

    • 21 Jul 2017 According to a SillaJen media release, the company has received approval from the China Food and Drug Administration (CFDA) to conduct this trial.
    • 24 Apr 2017 According to a SillaJen Biotherapeutics media release, company has enrolled the first European patient in this study this triggers a $4 million USD milestone to be paid to SillaJen by Transgene.
    • 20 Oct 2016 According to a Transgene media release, recruitment of the first European patient is expected at the end of the year 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top